Latest Headlines

Latest Headlines

Astellas bets on Immunomic's allergy vaccine in a $75M deal

Astellas Pharma is teaming up with biotech Immunomic Therapeutics on a vaccine that could relieve a common allergy that affects millions in its native Japan.

Merck KGaA abandons Symphogen's cancer drug ahead of Phase III

Merck KGaA, in the process of paring down its pipeline, is walking away from a $625 million deal with Symphogen and handing back the company's lead asset, a targeted cancer treatment in midstage trials.

AstraZeneca bolts together a top transatlantic team for CRISPR R&D

In a broad-ranging slate of tech collaborations, AstraZeneca is allying itself with several top research institutions to hone its ability to apply CRISPR gene editing techniques to its drug development work. And the pharma giant used this alliance to pick some of the best brains in the business, without turning to any of the pioneers who have recently spawned a lineup of upstart biotechs.

PhytoTech debuts on Australian stock exchange and will use funds for medical marijuana patch

Australia's PhytoTech Medical last week became the country's first medical marijuana company to first be listed on the country's Australian Securities Exchange, where it raised AUS $5.9 million ($4.7 million) in support of its single-use vaporizer to administer medical marijuana at a precise dosage.

Kaléo cuts price of auto-injector for opioid overdose in partnership with Clinton Foundation

In a win for the Clinton Foundation's goal of preventing 10,000 prescription drug-related deaths over 5 years, privately held kaléo agreed to sell its Evzio Auto-Injector to universities and other institutional buyers at the low federal price.

Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test

Sequenom is teaming up with Cypher Genomics to develop a noninvasive prenatal test using the company's advanced genome interpretation screening technology, eyeing a bigger share of an increasingly competitive market.

bioMérieux and Astute Medical join forces on acute kidney injury test

French in vitro diagnostics outfit bioMérieux and Astute Medical are teaming up to develop Astute's test for acute kidney injury, continuing the companies' recent diagnostics winning streak and helping them capitalize on a growing market.

Kite expands its immuno-oncology brain trust in the CAR-T footrace

Kite Pharma, contending with a slew of rivals in the newfangled field of immuno-oncology, has aligned itself with a pioneer in the field, teaming up with an Israeli university to work on treatments that train the body's own defenses on cancerous growth.

B. Braun partners with Cohera to sell TissuGlu in some European countries

Medical supply company B. Braun will be selling the surgical adhesive TissuGlu from startup Cohera Medical in Germany, Spain and Portugal under a new deal. The product received an approvable letter from the FDA in early January. At that time, Cohera said it expected FDA approval within a few weeks, but it hasn't come through quite yet.

AbbVie, Unilife enter into drug delivery partnership

AbbVie selected Unilife as its drug delivery partner. AbbVie paid $5 million to enter into the development and supply agreement.